of P e d i a t r i c s and Urology, Boston. We have p r e v i o u s l y described r e s u l t s w i t h a novel form o f adoptive immunotherapy using i n v i t r o immunized ( I V I ) autologous lymphocytes. We now r e p o r t r e s u l t s from an on-going study using an improved v e r s i o n of t h a t method. P a t i e n t lymphoc y t e s a r e d e p l e t e d o f suppressor T -c e l l s and i n v i t r o immunized f o r 60 hours i n medium c o n t a i n i n g autologous serum, mixed lymphoc y t e c u l t u r e s u p e r n a t a n t and a 3M KC1 a.atologous twnor e x t r a c t . The r e s u l t a n t I V I c e l l s a r e washed, d e p l e t e d again of suppressor c e l l s and i n f u s e d i n t o t h e p a t i e n t . A l l p a t i e n t s a l s o r e c e i v e c i m e t i d i n e t o block i n vivo suppressor c e l l s . P a t i e n t s w i l l be t r e a t e d monthly f o r 6 months. To d a t e , 30 p a t i e n t s have received a t o t a l o f 113 c e l l i n f u s i o n s , a l l d e l i v e r e d on an o u t p a t i e n t b a s i s , (average of l o 9 I V I c e l l s / i n f u s i o n ) . Toxicity has been minimal, c o n s i s t i n g o n l y of mild, t r a n s i e n t f e v e r and c h i l l s accompanying 42 of t h e i n f u s i o n s ( 3 7 % ) . Twenty-one p a t i e n t s have reached t h e f i r s t e v a l u a t i o n t i m q o i n t a t 3 months. (M~=minor response;PR=partial response;CR=complete response) This approach t o immunotherapy is s a f e and appears t o be b i o l o g i c a l l y a c t i v e , i n t h a t 7 of 21 evaluable p a t i e n t s (33%) have evidence of s t a b l e d i s e a s e o r o b j e c t i v e response a f t e r only 3 months of t r e a t n e n t . We have p r e v i o u s l y described t h a t thymic hormones might h e u s e f u l i n t h e treatment of h i s t i o c y t o s i s -X . Based on t h o s e d a t a , t h e O f f i c e o f Orphan Products Development a t t h e FDA i s sponsoring a randomized, double-blind, placebo-controlled c l i n i c a l s t u d y t o determine i f Suppressin A, a mixture of thymic hormones t h a t s p e c i f i c a l l y induce t h e d i f f e r e n t i a t i o n o f suppress o r T-lymphocytes, i s b i o l o g i c a l l y a c t i v e i n histiocytosis-X. P a t i e n t s a r e randomized t o r e c e i v e e i t h e r Suppressin A o r placebo f o r 42 days, a f t e r which they a r e re-evaluated and t h e codebroken. To h e l p i n t h e e v a l u a t i o n of b i o l o g i c a l a c t i v i t y , f o u r d i s t i n c t c l i n i c a l s c o r i n g systems were c r e a t e d : 1)organ s p e c i f i c ; 2)whole body; 3 ) v i t a l systems ( r e s p i r a t o r y , h e p a t i c and hematopoetic f u n c t i o n ) ; and 4 ) o v e r a l l performance s t a t u s . The r e s u l t s t o d a t e from t h e i n i t i a l 1 3 p a t i e n t s who have completed t h e six-week t r e a t m e n t course i n t h i s on-going study a r e : Scoring System Suppressin A (N=8) 
GENERATED BY IN VITRO IMMUNIZATION
, M.E. Osband and G.A. C a r p i n i t o , Boston U Sch Med and Boston C i t y Hosp, Dept of P e d i a t r i c s and Urology, Boston.
We have p r e v i o u s l y described r e s u l t s w i t h a novel form o f adoptive immunotherapy using i n v i t r o immunized ( I V I ) autologous lymphocytes. We now r e p o r t r e s u l t s from an on-going study using an improved v e r s i o n of t h a t method. P a t i e n t lymphoc y t e s a r e d e p l e t e d o f suppressor T -c e l l s and i n v i t r o immunized f o r 60 hours i n medium c o n t a i n i n g autologous serum, mixed lymphoc y t e c u l t u r e s u p e r n a t a n t and a 3M KC1 a.atologous twnor e x t r a c t . The r e s u l t a n t I V I c e l l s a r e washed, d e p l e t e d again of suppressor c e l l s and i n f u s e d i n t o t h e p a t i e n t . A l l p a t i e n t s a l s o r e c e i v e c i m e t i d i n e t o block i n vivo suppressor c e l l s . P a t i e n t s w i l l be t r e a t e d monthly f o r 6 months. To d a t e , 30 p a t i e n t s have received a t o t a l o f 113 c e l l i n f u s i o n s , a l l d e l i v e r e d on an o u t p a t i e n t b a s i s , (average of l o 9 I V I c e l l s / i n f u s i o n ) . Toxicity has been minimal, c o n s i s t i n g o n l y of mild, t r a n s i e n t f e v e r and c h i l l s accompanying 42 of t h e i n f u s i o n s ( 3 7 % ) . Twenty-one p a t i e n t s have reached t h e f i r s t e v a l u a t i o n t i m q o i n t a t 3 months. (M~=minor response;PR=partial response;CR=complete response) This approach t o immunotherapy is s a f e and appears t o be b i o l o g i c a l l y a c t i v e , i n t h a t 7 of 21 evaluable p a t i e n t s (33%) have evidence of s t a b l e d i s e a s e o r o b j e c t i v e response a f t e r only 3 months of t r e a t n e n t . We have p r e v i o u s l y described t h a t thymic hormones might h e u s e f u l i n t h e treatment of h i s t i o c y t o s i s -X . Based on t h o s e d a t a , t h e O f f i c e o f Orphan Products Development a t t h e FDA i s sponsoring a randomized, double-blind, placebo-controlled c l i n i c a l s t u d y t o determine i f Suppressin A, a mixture of thymic hormones t h a t s p e c i f i c a l l y induce t h e d i f f e r e n t i a t i o n o f suppress o r T-lymphocytes, i s b i o l o g i c a l l y a c t i v e i n histiocytosis-X. P a t i e n t s a r e randomized t o r e c e i v e e i t h e r Suppressin A o r placebo f o r 42 days, a f t e r which they a r e re-evaluated and t h e codebroken. To h e l p i n t h e e v a l u a t i o n of b i o l o g i c a l a c t i v i t y , f o u r d i s t i n c t c l i n i c a l s c o r i n g systems were c r e a t e d : 1)organ s p e c i f i c ; 2)whole body; 3 ) v i t a l systems ( r e s p i r a t o r y , h e p a t i c and hematopoetic f u n c t i o n ) ; and 4 ) o v e r a l l performance s t a t u s . The r e s u l t s t o d a t e from t h e i n i t i a l 1 3 p a t i e n t s who have completed t h e six-week t r e a t m e n t course i n t h i s on-going study a r e : Scoring System Suppressin A (N=8) 
TREATMENT OF HISTIOCYTOSIS-X WITH SUPPRESSIN
-
t a i n d i c a t e b i o l o g i c a l a c t i v i t y o f Suppressin A i n t h e t r e a t m e n t of h i s t i o c y t o s i s -X .
These e a r l y t r e n d s of s i g n i f i c a n c e need t o b e confirmedthrough f u r t h e r p a t i e n t recruitment and study. Epstein-Barr Virus (EBV)-related lymphomas ( L ) and B c e l l lymphoproli f e r a t i v e d i s e a s e s (LPD) a r e recognized with increasing frequency i n p t s a f t e r organ and mismatched a l l o g e n e i c bone rnarrow t r a n s p l a n t a t i o n (BMT). The high incidence may be due t o t h e profound immune suppression, m u l t i p l e copies o r unique characteri s t i c s of t h e v i r a l DNA. W e i n v e s t i g a t e d tumor DNA f r m 8 p t s with L o r LPD post-BMT and 1 post-renal t r a n s p l a n t a t i o n f o r EBV c l o n a l i t y and rearrangement of v i r a l EBV DNA. Tumor t i s s u e from a1 1 p t s contained m u l t i p l e (8-50) copies of EBV DNA a s detected by probing Southern b l o t s with r a d i o a c t i v e EBV probes. To d e t e rmine whether t h e EBV DNA was i n a c i r c u l a r o r l i n e a r configurat i o n , we probed t h e b l o t s of BamHI-digested p t DNAs with a Dam NJ het fragment. The NJ het region i s highly v a r i a b l e , t h u s a s i n g l e band suggests a clonal p r o l i f e r a t i o n of t h e v i r u s . The samples with 2 o r m r e bands represent e i t h e r oligoclonal virus o r l i n e a r EBV i n tumor t i s s u e . 6/9 p t DNAs had a s i n g l e band suggesting presence of c i r c u l a r EBV DNA. 2/9 had 2 bands of d i f f e r e n t s i z e s t h a t may r e p r e s e n t l i n e a r DNA o r d i f f e r e n t v i r u s s t r a i n s . One pt had evidence of c i r c u l a r and l i n e a r DNA, o r p o s s i b l e multiple s t r a i n s of EBV s i n c e 3 bands of v i r a l DNA were seen with t h e NJ het probe. Since 719 p t s had s i n g l e bands (suggesting c i r c u l a r , clonal ERV DNA when probed with NJ Het) t h i s may i n d i c a t e t h a t t h e c i r c u l a r DNA i s t r a n s c r i b i n g v i r a l genes important i n i n i t i a t i n g o r maintaining t h e LPD and L. 
CHARACTERIZATION OF EPSTEIN-BARR VIRUS GENOMES IN

Association of s e v e r e thrombocytopenia r e l a t e d t o increased d e s t r u c t i o n of p l a t e l e t s and a d m i n i s t r a t i o n of A M D h a s r e c e n t l y been reported (J P e d i a t r 104:611, 1985). To i n v e s t i g a t e t h e e t i o l o g y of t h i s phenomenon, we reviewed t h e c l i n i c a l and l a b o r a t o r y s t a t u s of 40 p e d i a t r i c p a t i e n t s with s o l i d tumors.
Twenty-eitht of t h e 40 p a t i e n t s received A M D a s p a r t of t h e i r treatment.
The presence of PAIg was determined by a previously described ELISA technique (Transfusion 24:348, 1984) . Eight of t h e 28 p a t i e n t s receiveing A M D demonstrated thrombocytopenia a s s o c i a t e d with increased d e s t r u c t i o n and n o t myelosuppression by t h e s e c r i t e r i a : a ) documentation of thrombocytopenia l e s s than 7 days a f t e r a d m i n i s t r a t i o n of AMD without t h e concomitant depression of o t h e r c e l l l i n e s and b) no evidence of disseminated i n t r a v a s c u l a r coagulation o r o t h e r non-specific consumption.
The me'ian p l a t e l e t count f o r thrombocytopenic p a t i e n t s was 80,000jul (range 13,000-149,000). Thrombocytopenia a s s o c i a t e d with p e r i p h e r a l d e s t r u c t i o n did n o t develop i n any of 12 p a t i e n t s n o t r e c e i v i n g AMD.
S i x of 8 thrombocytopenic p a t i e n t s on AMD had evidence of PAIg, while 9 of 19 non-thrombocytopenic A M D p a t i e n t s demonstrated PAIg. Also, 5 of 10 p a t i e n t s n o t r e c e i v i n g AMD had evidence of PAIg. Although thrombocytopenia a s s o c i a t e d with increased d e s t r u c t i o n was seen i n n e a r l y a t h i r d of p a t i e n t s r e c e i v i n g AMD, t h i s phenomenon could n o t be a s s o c i a t e d with an i n c r e a s e i n PAIg. In patients with sickle cell syndromes, EP levels may be markedly elevated. In 249 patients with sickle cell syndromes, we measured EP, ALAD, and ALAD after reactivation with dithiothreitol (ALADSH), in parallel with reticulocytes and pyruvate kinase (PA?. two agedependent parameters. EP, ALAD, ALADSH, reticulocytes and PK were much higher t b a i~ normal in all patients, with the most marked elevztion i n patients with homozygous sickle cell disease. In many cases, the elevation of EP resulted from free protoporphyrin base, rather then Zn-protoporphyrin. The logarithm of EP was correlated both with reticulocytes and with the logarithm of PK; the regression lines intersected the normal ranges for EP and reticulocytes and for EP and PK respectively. For ALAD and ALADSH, there were similar correlations; however, the regression lines remained well above the normal ranges without interse'cting them. The in vivo tl/z in the eryth:ocytes of both ALAD and ALADSH were estimated on discontinuous gradients of arabino-galactane at 443 days, indicating an age-dependent loss of enzyme activity, and not just oxidation of SHgroups with ?ime. The in vivo ti12 of EP is 60 days (JCI 56: 1519 (JCI 56: , 1975 ).
These data indicate that both EP and ALAD are increased i n sickle cell syndromes as a result of young red cell age. However, the higher ALAD values and the unusual protoporphyrin species suggest additional factors, probably some degree of dyserythropoiesis or the presence of large numbers of normoblasts i n these asplenic individuals.
